Market Overview

UPDATE: Stifel Initiates Coverage on Tekmira, Notes "Enthusiasm" for RNAi

Related TKMR
Tekmira Pharmaceuticals, Lakeland Industries Moving On Possible Ebola Case In California
Falcon Edge Takes Passive Stake In Tekmira Pharmaceuticals

In a report published Friday, Stifel analyst Stephen Willey initiated coverage on Tekmira Pharmaceuticals (NASDAQ: TKMR) with a Buy rating and $19.00 price target.

Willey noted that Tekmira is looking to capitalize on the growing “enthusiasm” for RNA interference (RNAi) based therapeutics by building a group of clinical candidates across indications including oncology and infectious disease. The analyst commented, “We believe the combination of optionality around a potentially best-in-class oncology candidate (TKM-PLK1) known to play a pivotal role in regulating critical cell cycle events across a number of different tumor types, a fully-funded collaboration with the U.S. government that could result in the early procurement of a first-in-class antiviral agent (TKM-Ebola), an expanding pipeline of wholly-owned opportunities with freedom-to-operate around additional RNAi targets of choice, and the continued monetization of its LNP technology creates a highly-favorable risk/reward at these levels.”

Stifel is positive on PLK1 as a validated oncogenic target and believed the drug will overcome historical limitations accompanying with conventional drug development. Willey specified, “We believe (1) encouraging mid-FY14 P1/2 expansion cohort data in patients with GI-derived neuroendocrine tumors (NETs) and adrenocortical carcinoma (ACC) would serve as the basis for initiating a pivotal P3 study by YE14; and (2) differential expression data demonstrating patients with PLK1+ hepatocellular carcinoma (HCC) have meaningfully-shorter (>2.5x) long-term survival rates provides a sound biological rationale for the soon-to-initiate P1 study.”

Shares of Tekmira closed at $13.00 on Thursday and are currently up 7.85% at $14.02.

Latest Ratings for TKMR

Nov 2014Stifel NicolausMaintainsBuy
Oct 2014Leerink SwannDowngradesOutperformMarket Perform
Aug 2014Leerink PartnersInitiates Coverage onOutperform

View More Analyst Ratings for TKMR
View the Latest Analyst Ratings

Posted-In: Stephen Willey StifelAnalyst Color Price Target Initiation Analyst Ratings


Related Articles (TKMR)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional